Hillhouse Investment Management’s Akero Therapeutics AKRO Stock Holding History

Hillhouse Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$5.7M	Buy	+297,521	New	+$5.64M	0.18%	27

Other funds holding AKRO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Hillhouse Investment Management's AKRO Position: Q2 2019 in Review

Hillhouse Investment Management opened a new position in Akero Therapeutics (AKRO) in Q2 2019: 297,521 shares worth $5.7M. The stake represents 0.18% of the portfolio and ranks #27 among its holdings.

48 funds tracked by Wall St. Rank hold AKRO as of Q2 2019.

Hillhouse Investment Management held 297,521 shares of Akero Therapeutics worth $5.7M as of Q2 2019.
Akero Therapeutics was a new Hillhouse Investment Management position in Q2 2019.
Akero Therapeutics made up 0.18% of Hillhouse Investment Management's portfolio in Q2 2019, its #27 holding.
48 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2019.

Based on Hillhouse Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.